If a variant has more than two submissions, it may have multiple conflicts and therefore be counted in more than one conflict column. If this is the case, the "Variants with any kind of conflict" cell will be less than the sum of the conflicted variants cells to its left.
| Variants with only 1 submission per condition | Variants with at least 2 submissions on the same condition and no conflicts |
Variants with a synonymous conflict (e.g. benign vs non-pathogenic) |
Variants with a confidence conflict (e.g. benign vs likely benign) |
Variants with a benign or likely benign vs uncertain conflict |
Variants with a category conflict (e.g. benign vs affects) |
Variants with a clinically significant conflict (e.g. benign vs pathogenic) |
Variants with any conflict |
|---|---|---|---|---|---|---|---|
| 85 | 162 | 2 | 44 | 32 | 0 | 18 | 83 |
Significance breakdown #
In the table below, cells that correspond to a term paired with itself represent synonymous conflicts, i.e. variants that have been annotated with different terms that map to the same standard term. To compare the terms that were actually submitted, check the box in the filters section at the top of this page.
| All conditions | ||||||
|---|---|---|---|---|---|---|
| Inherited breast cancer and ovarian cancer | pathogenic | likely pathogenic | uncertain significance | likely benign | benign | |
| pathogenic | 2 | 13 | 5 | 0 | 0 | |
| likely pathogenic | 14 | 0 | 4 | 0 | 1 | |
| uncertain significance | 6 | 7 | 0 | 9 | 1 | |
| likely benign | 0 | 0 | 15 | 0 | 4 | |
| benign | 0 | 0 | 8 | 14 | 0 | |
Condition to condition summary #
Total conditions: 22
| Condition | Variants with only 1 submission per condition | Variants with at least 2 submissions on the same condition and no conflicts |
Variants with a synonymous conflict (e.g. benign vs non-pathogenic) |
Variants with a confidence conflict (e.g. benign vs likely benign) |
Variants with a benign or likely benign vs uncertain conflict |
Variants with a category conflict (e.g. benign vs affects) |
Variants with a clinically significant conflict (e.g. benign vs pathogenic) |
Variants with any conflict |
|---|---|---|---|---|---|---|---|---|
| not provided | 0 | 163 | 0 | 36 | 28 | 0 | 15 | 73 |
| not specified | 0 | 29 | 0 | 12 | 18 | 0 | 3 | 31 |
| Breast and/or ovarian cancer | 0 | 78 | 0 | 15 | 3 | 0 | 2 | 20 |
| BRCA2-related disorder | 0 | 23 | 0 | 3 | 1 | 0 | 2 | 6 |
| CHEK2-related disorder | 0 | 2 | 0 | 4 | 0 | 0 | 2 | 6 |
| Breast cancer, susceptibility to | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 3 |
| Breast and colorectal cancer, susceptibility to | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 2 |
| Breast-ovarian cancer, familial, susceptibility to, 3; Fanconi anemia complementation group O | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 2 |
| Fanconi anemia complementation group N; Pancreatic cancer, susceptibility to, 3; Breast-ovarian cancer, familial, susceptibility to, 5 | 0 | 5 | 0 | 2 | 0 | 0 | 0 | 2 |
| Hereditary cancer | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 2 |
| Inherited ovarian cancer (without breast cancer) | 0 | 30 | 0 | 2 | 0 | 0 | 0 | 2 |
| PALB2-related disorder | 0 | 7 | 0 | 2 | 0 | 0 | 0 | 2 |
| Breast cancer, susceptibility to; Prostate cancer susceptibility | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| CHEK2-related cancer risk | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Inherited breast cancer and ovarian cancer | 298 | 31 | 0 | 1 | 0 | 0 | 0 | 1 |
| Pancreatic cancer, susceptibility to | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Pancreatic cancer, susceptibility to, 3; Breast-ovarian cancer, familial, susceptibility to, 5 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Predisposition to cancer | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 1 |
| RAD51C-related disorder | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| TUMOR PREDISPOSITION SYNDROME 4, BREAST | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| TUMOR PREDISPOSITION SYNDROME 4, BREAST/PROSTATE | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| autosomal dominant PALB2-related cancer predisposition | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 1 |
All variants with conflicting interpretations #
Total variants: 83